Sustainability. We mean it.

Impact Opportunities Equity, Q4 2023

29 December 2023 |
Until recently, countering both diabetes and obesity largely focused on prevention – unfortunately with limited success. However, recent medical advances present the opportunity to manage diabetes more effectively, and to treat both type-2 diabetes and obesity with highly effective drugs – something we view as a major impact opportunity.
Impact Opportunities Equity, Q4 2023

Fast reading

  • Around 537 million people worldwide have diabetes1, while over 650 million are obese2 – and numbers are rising rapidly. With both conditions linked to a wide range of other serious medical issues, countering these two silent killers is one of the key healthcare and social challenges of the 21st
  • Diabetes is not a new problem; however, the impact of modern lifestyles has resulted in a huge surge in cases of type-2 diabetes. Given the limited impact of public health campaigns, effective treatments are vital to reduce the social and economic cost.
  • Being overweight is both a major cause of type-2 diabetes and a factor in numerous other diseases, including heart attacks, strokes, osteoarthritis and cancer. As obesity becomes recognised as a public health issue, the pathway to effective treatment is opening.

Impact Opportunities Equity, Q4 2023

Archive: Previous editions

1 Facts & figures page of the International Diabetes Federation website. Accessed 24 November 2023.

2 Obesity and overweight page of the World Health Organization website. Accessed 24 November 2023.

Impact Opportunities Equity, Q4 2023

Related insights

Lightbulb icon

Get the latest insights straight to your inbox